Interferons in the treatment of myeloproliferative neoplasms
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Man...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-02-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207241229588 |
| _version_ | 1797302314494590976 |
|---|---|
| author | Pankit Vachhani John Mascarenhas Prithviraj Bose Gabriela Hobbs Abdulraheem Yacoub Jeanne M. Palmer Aaron T. Gerds Lucia Masarova Andrew T. Kuykendall Raajit K. Rampal Ruben Mesa Srdan Verstovsek |
| author_facet | Pankit Vachhani John Mascarenhas Prithviraj Bose Gabriela Hobbs Abdulraheem Yacoub Jeanne M. Palmer Aaron T. Gerds Lucia Masarova Andrew T. Kuykendall Raajit K. Rampal Ruben Mesa Srdan Verstovsek |
| author_sort | Pankit Vachhani |
| collection | DOAJ |
| description | Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current therapeutic landscape, pegylated interferons are recommended for use in the treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. We review recent efficacy, molecular response, and safety data for the two available pegylated interferons, peginterferon alfa-2a (Pegasys) and ropeginterferon alfa-2b-njft (BESREMi). The practical management of interferon-based therapies is discussed, along with our opinions on whether to and how to switch from hydroxyurea to one of these therapies. Key topics and questions related to use of interferons, such as their safety and tolerability, the significance of variant allele frequency, advantages of early treatment, and what the future of interferon therapy may look like, will be examined. Pegylated interferons represent an important therapeutic option for patients with MPNs; however, more research is still required to further refine interferon therapy. |
| first_indexed | 2024-03-07T23:35:02Z |
| format | Article |
| id | doaj.art-f914014456cf435ebd924c6e619ff22a |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-03-07T23:35:02Z |
| publishDate | 2024-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-f914014456cf435ebd924c6e619ff22a2024-02-20T10:03:27ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152024-02-011510.1177/20406207241229588Interferons in the treatment of myeloproliferative neoplasmsPankit VachhaniJohn MascarenhasPrithviraj BoseGabriela HobbsAbdulraheem YacoubJeanne M. PalmerAaron T. GerdsLucia MasarovaAndrew T. KuykendallRaajit K. RampalRuben MesaSrdan VerstovsekInterferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current therapeutic landscape, pegylated interferons are recommended for use in the treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. We review recent efficacy, molecular response, and safety data for the two available pegylated interferons, peginterferon alfa-2a (Pegasys) and ropeginterferon alfa-2b-njft (BESREMi). The practical management of interferon-based therapies is discussed, along with our opinions on whether to and how to switch from hydroxyurea to one of these therapies. Key topics and questions related to use of interferons, such as their safety and tolerability, the significance of variant allele frequency, advantages of early treatment, and what the future of interferon therapy may look like, will be examined. Pegylated interferons represent an important therapeutic option for patients with MPNs; however, more research is still required to further refine interferon therapy.https://doi.org/10.1177/20406207241229588 |
| spellingShingle | Pankit Vachhani John Mascarenhas Prithviraj Bose Gabriela Hobbs Abdulraheem Yacoub Jeanne M. Palmer Aaron T. Gerds Lucia Masarova Andrew T. Kuykendall Raajit K. Rampal Ruben Mesa Srdan Verstovsek Interferons in the treatment of myeloproliferative neoplasms Therapeutic Advances in Hematology |
| title | Interferons in the treatment of myeloproliferative neoplasms |
| title_full | Interferons in the treatment of myeloproliferative neoplasms |
| title_fullStr | Interferons in the treatment of myeloproliferative neoplasms |
| title_full_unstemmed | Interferons in the treatment of myeloproliferative neoplasms |
| title_short | Interferons in the treatment of myeloproliferative neoplasms |
| title_sort | interferons in the treatment of myeloproliferative neoplasms |
| url | https://doi.org/10.1177/20406207241229588 |
| work_keys_str_mv | AT pankitvachhani interferonsinthetreatmentofmyeloproliferativeneoplasms AT johnmascarenhas interferonsinthetreatmentofmyeloproliferativeneoplasms AT prithvirajbose interferonsinthetreatmentofmyeloproliferativeneoplasms AT gabrielahobbs interferonsinthetreatmentofmyeloproliferativeneoplasms AT abdulraheemyacoub interferonsinthetreatmentofmyeloproliferativeneoplasms AT jeannempalmer interferonsinthetreatmentofmyeloproliferativeneoplasms AT aarontgerds interferonsinthetreatmentofmyeloproliferativeneoplasms AT luciamasarova interferonsinthetreatmentofmyeloproliferativeneoplasms AT andrewtkuykendall interferonsinthetreatmentofmyeloproliferativeneoplasms AT raajitkrampal interferonsinthetreatmentofmyeloproliferativeneoplasms AT rubenmesa interferonsinthetreatmentofmyeloproliferativeneoplasms AT srdanverstovsek interferonsinthetreatmentofmyeloproliferativeneoplasms |